GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on Jun 27, 2025
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GlaxoSmithKline Pharmaceuticals has notified the stock exchanges about its 100th Annual General Meeting scheduled for Friday, June 27, 2025 at 11:00 a.m., to be held via Video Conferencing. Shareholders will consider adopting the audited financial statements for FY ending March 31, 2025, confirm the interim dividend, and approve a final dividend of ₹42 per equity share. The meeting also includes the re-appointment of Mr. Juby Chandy (retiring by rotation) and Dr. Sunita Maheshwari as an Independent Director for a second term of three years (May 18, 2025 to May 17, 2028). Additionally, shareholders will vote on the appointment of Parikh & Associates as Secretarial Auditors for five years (FY2025-26 to FY2029-30) at a proposed fee of ₹2.5 lakh per year, and ratify ₹7.35 lakh remuneration to R. Nanabhoy & Company as Cost Auditors. The record date for final dividend eligibility is May 30, 2025, with remote e-voting open from June 23 to June 26, 2025.
The proposed ₹42 final dividend, combined with prior interim dividends, signals a consistent shareholder return policy and provides clarity on near-term income for investors. Routine governance items like director re-appointments and auditor changes carry no material risk and are unlikely to move the stock significantly.